Brain Tumor Diagnosis and Treatments Market, By Diagnosis Type (MRI, CT- Scan, Tissue Sampling, PET-CT scan, Cerebral Arteriogram, and Others), By Treatment therapy (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, and Targeted Therapy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034

Brain Tumor Diagnosis and treatment Market Size was valued at US$ 3114.5 million in 2024 and is projected to grow at a CAGR of 7.8% to reach US$ 6228.9 million by 2034.

Brain tumor is diagnosed, a neurological examination, brain imaging, and, if possible, a biopsy is typically performed. Numerous tests to assess neurological abilities like balance, hearing, vision, and reflexes may be part of a neurological exam. A number of imaging methods, such as MRI, CT (or CAT) scan, X-rays, and rarely an angiography, can be performed to detect the tumor, locate it, and/or evaluate brain function.Doctors will diagnose the brain tumor and determine the course of treatment based on the results of other tests if a biopsy (the collection and examination of tissue samples) cannot be done in a safe manner. If a biopsy was feasible, medical professionals might examine the tumor tissue and ascertain the tumor's grade, or degree of aggressiveness.

Brain Tumor Research, a research organization, reported a drastic delay in the diagnosis and treatment approaches, such as chemotherapy and radiotherapy for different types of brain tumors. However, the market is gradually stabilizing as COVID-19 cases are declining, resulting in the return of the normal demand levels for brain tumor diagnostics. Thus, COVID-19 is expected to significantly impact the brain tumor diagnostics market over the forecast period.

Brain Tumor Diagnostics Market Drivers and Restrains:

Market Drivers:  

Expanding on Chemotherapies and Raising Awareness to Serve as the Main Growth Engines

• The need for efficient treatment has increased due to an increase in the prevalence rate of brain tumors. For example, according to the American Society of Clinical Oncology (ASCO), the incidence rate of brain tumors increased by 2.6% over the previous year. In the US, primary malignant brain tumor diagnoses are anticipated to be 22,850 instances. Moreover, the market for brain tumors is being driven by the growing elderly population.
  Because of this, multinational corporations are allocating a sizeable percentage of their earnings to research and development in order to create new drugs.

Increasing number of technical developments

• Rising levels of investment in research and development activities, would contribute to the expansion of the brain tumor diagnosis and treatment market during the anticipated period.
• Due to advancement in techniques for the removal of brain tumor like chemo therapies and lasic surgeries the necessity of these diagnostic practices has been increased it has a good impact in market.

Restrains in the Brain Tumor Diagnostics Market:

High Implementation Costs

• Implementing therapy machinery like MRI, Image scanner and providing supervision can require significant upfront investment, including the cost of the software itself, customization, and integration with existing systems. This can be a barrier for smaller companies with limited budgets.
• In addition to the initial outlay, there are continuing costs for user training and maintenance. Some businesses may find it difficult to continue their therapy efforts due to these escalating expenditures.

Lack of Standardization

• The regulatory landscape for Brain Tumor Diagnosis is constantly evolving, with new guidelines and requirements emerging regularly. Keeping up with these changes and adjusting reporting practices accordingly can be a daunting task for companies.
• While there are several Brain Tumor Diagnosis frameworks, there is no universal standard, which can create confusion and inconsistency in reporting practices. Companies may find it challenging to choose the right framework and ensure their reporting meets multiple stakeholders' requirements.

Brain Tumor Diagnosis Market is segmented based on based on by Diagnosis Type, by Treatment therapy and Region.

Diagnosis Type Insight

• MRI (Magnetic Resonance Imaging)-MRI uses powerful magnets and radio waves to create detailed images of organs and tissues inside the body. It is particularly useful for detecting aMnormalities in soft tissues like the brain, muscles, and joints.
• CT scan (Computed Tomography)- A CT scan combines X-ray images taken from different angles around the body and uses computer processing to create cross-sectional images. It provides detailed information about bones, organs, and soft tissues, aiding in the diagnosis of various conditions.
• Tissue Sampling (Biopsy)-Tissue sampling involves removing a small sample of tissue from the body for examination under a microscope. It helps diagnose diseases such as cancer and infections by analysing the cellular structure and identifying aMnormalities.
• PET-CT scan (Positron Emission Tomography-Computed Tomography): PET-CT combines functional information from PET, which detects the activity of cells in the body, with detailed anatomical images from CT. It is important in interpreting conditions like cancer, evaluating treatment effectiveness, and detecting aMnormalities not visible on other different imaging tests.
• Cerebral Arteriogram (Cerebral Angiogram)- This diagnostic procedure involves injecting contrast dye into the blood vessels of the brain and taking X-ray images. It helps visualize blood flow and detect aMnormalities such as aneurysms, arteriovenous malformations (AVMs), and narrowing of blood vessels (stenosis) in the brain.

Treatment Therapy Type Insights

• Surgery-Surgery involves physically removing or repairing diseased tissues or organs from the body. It is often used to remove tumors, repair injuries, or correct structural aMnormalities. Surgeons use precise tools and techniques to minimize damage to surrounding healthy tissue and promote healing to the patient.
• Radiation Therapy- Radiation therapy uses high-energy rays or particles to target and destroy brain cancer cells or shrink tumors. It works by damaging the DNA inside the targeted cells, preventing them from dividing and growing. Radiation may be delivered externally (external beam radiation) or internally (brachytherapy), depending on the type and location of the cancer.
• Chemotherapy-Chemotherapy involves using drugs to kill or slow the growth of cancer cells throughout the body. These drugs can be administered orally or intravenously and work by targeting rapidly dividing cells, which includes cancer cells. Chemotherapy is often used in combination with other treatments like surgery or radiation therapy.
• Immunotherapy- Immunotherapy aims to boost the body's immune system to recognize and attack cancer cells. It includes various treatments such as monoclonal antibodies, checkpoint inhibitors, cytokines, and cancer vaccines. Immunotherapy can support the immune system to better target and destroy cancer cells while sparing healthy cells.
• Targeted Therapy-These therapy uses drugs or other substances to specifically target aMnormalities present within cancer cells. These aMnormalities may include mutations or specific proteins that contribute to the growth and survival of cancer cells.

Brain Tumor Diagnosis and Treatment Market Regional Insights:

On region the Brain Tumor Diagnosis and Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America particularly the United States and Canada, is a significant market for Brain tumor diagnosis and treatment market due to strong regulatory frameworks and increasing investor demand for transparency in sustainability practices.
• Asia Pacific region is rapidly growing in the Brain Tumor Diagnosis and Treatment Market due to increasing regulatory developments, investor interest, and corporate sustainability efforts. Countries like Japan, South Korea, and Australia are enhancing their therapy treatment machinery and infrastructural requirements. China is also beginning to emphasize Brain tumor diagnosis and treatment as part of its broader public health economic reforms.
• Europe is expected to dominate the target market growth and this region is also considered a leader in the Brain tumor diagnosis and treatment market, driven by rigorous regulations and a strong cultural emphasis on sustainability and Healthcare responsibility.
• Latin America is emerging as a promising market for Brain tumor diagnosis and treatment market, driven by increasing awareness and regulatory initiatives. There is a growing awareness of the importance of Brain and Brain cells among businesses and investors in Latin America. This has led to increased adoption of good therapy like chemo practices.
• Middle East & Africa region is a growing interest from both regional and international investors in this brain tumor diagnosis and treatment, driving companies to adopt therapy setup tools to enhance transparency and attract investment.  

Brain Tumor Diagnosis and Treatment Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Brain Tumor Diagnosis and Treatment Market report based on By Product, By End-User and Region:

Brain Tumor Diagnosis and Treatment Market, By Diagnosis type:

• MRI (Magnetic Resonance Imaging)
• CT- Scan
• Tissue Sampling
• PET-CT can
• Cerebral Arteriogram
• Others

Brain Tumor Diagnosis and Treatment Market, By Treatment Therapy:

• Surgery
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy

Brain Tumor Diagnosis and Treatment Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Brain Tumor Diagnosis and Treatment Market includes Pfizer Inc., Toshiba Medical Systems, GE Healthcare, AstraZeneca, Merck & Co., Inc., Siemens Healthineers, Carestream Health, Hitachi Medical Corporation, Philips Healthcare, Shimadzu Corporation.

• In February 2023: Roche announced the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer. It is helpful for brain tumor patients and market industry for this growth factor of Brain Tumor Diagnosis and treatment market. clinical trials are still going on to check the efficiency and result of the treatment provided.
• In January 2023: Datar Cancer Genetics Inc. received FDA breakthrough device designation for the TriNetra-Glio blood test to help in the diagnosis of brain tumors. The TriNetra-Glio liquid biopsy is intended to detect the cells released in the blood from the brain tumor, which are extremely rare and difficult to detect. TriNetra-Glio is indicated for patients with intracranial space-occupying lesions where a biopsy is unviable due to the inaccessibility of the tumor or a comorbidity, the refusal of the patient, or a non-diagnostic result from a biopsy. The company said the indication for use will eventually be expanded to include diagnosis of all patients with brain lesions.

• Pfizer Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Business Strategy Overview
• Toshiba Medical Systems
• GE Healthcare
• AstraZeneca
• Merck & Co., Inc.
• Siemens Healthineers
• Carestream Health
• Hitachi Medical Corporation
• Philips Healthcare
• Shimadzu Corporation

“*” marked represents similar segmentation in other categories in the respective section.